Submissions
2
2 included · 0 excluded
Overall compliance
80%
Mean across criteria
Fully compliant cases
50%
1 of 2
High-risk medicines
100%
2 of 2 included
Compliance by criterion
NICE NG5 medicines optimisation, NHS structured medication review guidance and STOPP/START v3
Structured medication review completed100% / 95%
Indication documented for regular medicines100% / 95%
Dose appropriateness reviewed50% / 95%
Drug interactions reviewed100% / 95%
Renal dosing reviewed / renal function documented50% / 95%
Hepatic considerations reviewed100% / 90%
Medicines reconciliation completed100% / 95%
Falls risk considered where relevant100% / 90%
Patient/carer involved in the review50% / 90%
STOPP/START considered where appropriate50% / 90%
Deprescribing opportunities identified100% / 80%
Pharmacy review completed100% / 90%
Consultant review completed50% / 80%
Medication changes documented100% / 95%
Rationale for changes documented50% / 95%
Monitoring plan documented100% / 90%
GP communication documented50% / 90%
Patient counselling documented50% / 90%
Action plan documented100% / 95%
Follow-up need assessed/documented100% / 90%
Compliance by location
Fully compliant reviews per location
Compliance trend
Weekly running compliance
Interpretation
Summary based on the current dataset
- Overall compliance across all 20 structured polypharmacy review criteria is 80%.
- 50% of included cases meet every audit criterion.
- Weakest area: Dose appropriateness reviewed at 50% (target 95%).
- Lowest-performing location: Respiratory Ward (0% fully compliant).
- Safety: 100% of included cases involved high-risk medicines — ensure local monitoring and escalation pathways are documented.
- Safety: 50% of included cases had high anticholinergic burden (3+) — prioritise deprescribing review where clinically appropriate.